{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["141(1)"],"submitter":["Groarke EM"],"pubmed_abstract":["Immune aplastic anemia (AA) is a severe blood disease characterized by T-lymphocyte- mediated stem cell destruction. Hematopoietic stem cell transplantation and immunosuppression are effective, but they entail costs and risks, and are not always successful. The Janus kinase (JAK) 1/2 inhibitor ruxolitinib (RUX) suppresses cytotoxic T-cell activation and inhibits cytokine production in models of graft-versus-host disease. We tested RUX in murine immune AA for potential therapeutic benefit. After infusion of lymph node (LN) cells mismatched at the major histocompatibility complex [C67BL/6 (B6)⇒CByB6F1], RUX, administered as a food additive (Rux-chow), attenuated bone marrow hypoplasia, ameliorated peripheral blood pancytopenia, preserved hematopoietic progenitors, and prevented mortality, wh"],"journal":["Blood"],"pagination":["72-89"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9837431"],"repository":["biostudies-literature"],"pubmed_title":["Efficacy of JAK1/2 inhibition in murine immune bone marrow failure."],"pmcid":["PMC9837431"],"pubmed_authors":["Wu Z","Manley AL","Chen J","Feng X","Groarke EM","Aggarwal N","Patel BA","Young NS","Gao S"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy of JAK1/2 inhibition in murine immune bone marrow failure.","description":"Immune aplastic anemia (AA) is a severe blood disease characterized by T-lymphocyte- mediated stem cell destruction. Hematopoietic stem cell transplantation and immunosuppression are effective, but they entail costs and risks, and are not always successful. The Janus kinase (JAK) 1/2 inhibitor ruxolitinib (RUX) suppresses cytotoxic T-cell activation and inhibits cytokine production in models of graft-versus-host disease. We tested RUX in murine immune AA for potential therapeutic benefit. After infusion of lymph node (LN) cells mismatched at the major histocompatibility complex [C67BL/6 (B6)⇒CByB6F1], RUX, administered as a food additive (Rux-chow), attenuated bone marrow hypoplasia, ameliorated peripheral blood pancytopenia, preserved hematopoietic progenitors, and prevented mortality, wh","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jan","modification":"2025-04-19T19:49:43.056Z","creation":"2025-04-19T19:49:43.056Z"},"accession":"S-EPMC9837431","cross_references":{"pubmed":["36130301"],"doi":["10.1182/blood.2022015898"]}}